Monistat 3 leads OTC vaginal yeast infection market with sales of $64.4 mil. -- IRI.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL MONISTAT 3 LEADS VAGINAL YEAST INFECTION MARKET with sales in food, drug and mass market channels of $64.4 mil., up 4.5% in the 52 weeks ended May 24, according to data from Chicago-based Information Resources, Inc. Monistat 7 had higher unit sales than the three-day product -- 5.3 mil. units -- but lower dollar sales ($56.7 mil.), reflecting the seven-day product's lower retail price ($9-$12 versus $13-$16). Monistat 7's dollar sales were down 10.1% from the comparable period the year before, and unit sales fell 5.2%. Both products contain 2% miconazole.